Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease (Q43106531)

14 November 2017

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease (English)

1 reference

14 November 2017

1 reference

1 reference

E Terpos

1

1 reference

14 November 2017

J Berenson

2

1 reference

14 November 2017

R J Cook

3

1 reference

14 November 2017

A Lipton

4

1 reference

14 November 2017

R E Coleman

5

1 reference

14 November 2017

8 April 2010

1 reference

14 November 2017

1 reference

14 November 2017

24

1 reference

14 November 2017

5

1 reference

14 November 2017

1043-1049

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2010.62

14 November 2017

0 references

cites work

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

inferred from DOI database lookup

7 January 2021

based on heuristic

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.62

1 reference

Dimensions Publication ID

14 November 2017

0 references

1 reference